Koyfin Home > Directory > Health Care > Revance Therapeutics > EV / EBITDA (ntm)

Revance Therapeutics EV / EBITDA (ntm) Chart (RVNC)

Revance Therapeutics annual/quarterly EV / EBITDA (ntm) from 2020 to 2020. Enterprise multiple, also known as the EBITDA multiple, is a ratio used to determine the value of a company. It uses the consensus estimate EBITA over the next twelve months (NTM). The enterprise multiple looks at a firm in the way a potential acquirer might by considering the company's debt, which other multiples such as P/E do not include.
Other Valuation Metrics:
  • Revance Therapeutics Market Cap for the quarter ending March 03, 2018 was $1,131m a 29.36% increase of 332m year over year
  • Revance Therapeutics Price / Book for the quarter ending March 03, 2018 was 4.18 a -6.42% decrease of -0.27 year over year
  • Revance Therapeutics Enterprise Value for the quarter ending March 03, 2018 was $850m a 27.67% increase of 235m year over year
View Chart On Koyfin